RT Journal Article
SR Electronic
A1 Rizzo, Toni
T1 High Efficacy Rates with Grazoprevir Plus Elbasvir in HCV Monoinfection and HCV/HIV Coinfection
JF MD Conference Express
YR 2014
FD SAGE Publications
VO 14
IS 48
SP 23
OP 24
DO 10.1177/155989771448018
UL http://mdc.sagepub.com/content/14/48/23.abstract
AB Grazoprevir is a highly potent hepatitis C virus (HCV)-specific NS3/4A protease inhibitor. Part A of a Study of the Combination Regimen Grazoprevir (MK-5172) and Elbasvir (MK-8742) ± Ribavirin in Participants With Chronic Hepatitis C [C-WORTHy; NCT01717326] reported efficacy of 89% to 100% in treatment-naïve noncirrhotic patients with HCV genotype-1 infection. This article discusses the expanded C-WORTHy Part B, which assessed the efficacy and safety of grazoprevir plus elbasvir with or without ribavirin in patients with HCV monoinfection and patients with HCV and human immunodeficiency virus coinfection.